ASTRO Virtual Meeting Center

Log-in / Create Account

Session Information

2008 Annual Meeting

Click here to go to the previous page

The Current Role of Trimodality Therapy in Stage III Non Small Cell Lung Cancer

Track : PAN

Program Code: PAN01

Date: Sunday, September 21, 2008

Time: 4:15 PM to 5:45 PM EST

Duration: 3470 Minutes

Location: 258

SPEAKER(S):

Jeffrey Bradley, Associate Professor, Washington University Medical School

Frank Detterbeck, Professor, Yale University School of Medicine

Martin Edelman, Director, Medical Thoracic Oncology, University of Maryland School of Medicine

Dr. Edelman is Professor of Medicine and Director of Medical Thoracic Oncology at the University of Maryland Greenebaum Cancer Center. Dr. Edelman received his medical degree from the Albany Medical College and performed his internship and residency in Internal Medicine and Fellowship in Hematology and Oncology at the Naval Medical Center San Diego. After leaving active military service, Dr. Edelman joined the faculty at the University of California, Davis and the VA Northern California Health Care System in 1990. He later became Chief of the Division of Hematology and Oncology at the VA. He was a member of the VA National Technical Advisory Group for Oncology and chaired the VA National Oncology Conference for four years. While at UC Davis he was co-director of the thoracic oncology program and developed several trials in lung cancer. In addition, he also initiated trials in GU malignancies, developmental therapeutics and supportive care. Dr. Edelman was a member of the Lung Cancer and GU committees of the Southwest Oncology Group (SWOG) and chaired two SWOG Phase II trials in lung cancer, both based upon pilot studies performed at UC Davis. In 1999, Dr. Edelman moved to the University of Maryland Greenebaum Cancer Center in Baltimore. He is the head of Medical Thoracic Oncology and clinical leader of the Experimental Therapeutics Program as well as the institutional Principal Investigator for the Cancer and Leukemia Group B (CALGB) at Maryland. Currently he leads trials in lung cancer in the CALGB and RTOG as well as a number of clinical and laboratory studies investigating new agents in cancer including benzoylphenylurea, UCN-01, COX-2 inhbitors, aurora kinase inhibitors and others at the University of Maryland. Dr.Edelman has served as a member of the NIH subcommittee H, the ASCO program committee and several NIH study sections. In addition, he is Associate Editor of the journal �Lung Cancer�.

Mohan Suntharalingam, University of Maryland Medical Center

LEARNER OUTCOMES:

Gain insight into the current state of the literature that addresses the potential role for trimodality therapy.
Correctly indentify appropriate patient selection factors when considering tri-modality therapy in stage III NSCLC from radiotherapy, chemotherapy and surgical pperspective.
Define optimal sequences of therapy designed to improve both local control and overall survival.